Interesting ...
AZ to showcase AZD0466 on 9 June 2023 at the European Hematology Association (EHA) 2023 Hybrid Congress
https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-showcases-scientific-advances-across-rare-and-malignant-haematological-conditions-at-eha-2023.html
- Preliminary ongoing Phase I/II safety and tolerability results of AZD0466, a Bcl-2/Bcl-xl inhibitor, will show it is tolerated as a monotherapy for patients with relapsed or refractory acute leukaemia.
AZD0466
Marconi, G
Safety and tolerability of AZD0466 as monotherapy for patients with advanced hematological malignancies - Preliminary results from an ongoing Phase I/II trial
Abstract # P537
Poster Presentation
9 June 2023
Interesting ... AZ to showcase AZD0466 on 9 June 2023 at the...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.005(4.00%) |
Mkt cap ! $54.36M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.0¢ | 12.0¢ | $53.97K | 420.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 70507 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 493895 | 3 |
View Market Depth
| Last trade - 15.14pm 19/09/2025 (20 minute delay) ? |
| SPL (ASX) Chart |